Table 2

Overview of the 20 possibly treatment related and/or serious adverse events in the 107 patients with SpA treated with infliximab for a total number of 191.5 patient-years. Disease duration is given in years

Patient NoAgeSexDiagnosisHLA-B27Duration Infliximab treatment (weeks)Treatment scheduleConcomitant treatmentAdverse eventDiscontinuation of infliximab
AS, ankylosing spondylitis; PsA, psoriatic arthritis; uSpA, undifferentiated SpA; NA, not assessed.
165MalePsANegative95 mg/kg at weeks 0, 2, and 6Prednisolone 10 mg/dayDisseminated tuberculosisYes
254MaleuSpANegative95 mg/kg at weeks 0, 2, and 6NoneDisseminated tuberculosisYes
346MaleASPositive285 mg/kg every 14 weeksNoneWound infection with Staphylococcus aureusNo
426MaleuSpAPositive15 mg/kg at week 0NoneSeptic-like arthritisYes
540MaleASPositive3710 mg/kg every 14 weeksNoneSepsisNo
649FemalePsANA485 mg/kg every 14 weeksMethotrexate 10 mg/weekRetropharyngeal abscess, Streptococcus pyogenesYes
732MaleASPositive685 mg/kg every 10 weeksNoneRetropharyngeal abscessYes
830MaleASPositive1245 mg/kg every 8 weeksNoneRetropharyngeal abscessNo
939MaleASPositive105 mg/kg at weeks 0, 2, and 6NoneTooth abscessNo
1037MalePsANA475 mg/kg every 14 weeksNoneTooth abscessNo
1157FemaleASPositive175 mg/kg every 8 weeksNoneAnal abscessNo
1250MaleASPositive135 mg/kg at weeks 0, 2 and 6NoneErysipelasNo
1340MaleASPositive725 mg/kg every 10 weeksNonePneumoniaNo
1459MaleASNA665 mg/kg every 10 weeksNonePyelonephritisNo
1574MalePsANA825 mg/kg every 10 weeksNoneSpinocellular carcinoma
of the skin
1649FemalePsAPositive205 mg/kg every 14 weeksNoneInfusion reactionNo
1728FemaleASNA285 mg/kg every 8 weeksNoneMild infusion reactionNo
1845MaleASPositive135 mg/kg at weeks 0, 2, and 6NonePalmoplantar pustulosisNo
1944MaleASPositive3410 mg/kg every 14 weeksNonePalmoplantar pustulosisNo
2044FemaleASPositive2310 mg/kg every 14 weeksNonePalmoplantar pustulosisNo